摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-[(1R)-1-phenylethyl]-1,3-benzoxazole-2-carboxamide

中文名称
——
中文别名
——
英文名称
N-[(1R)-1-phenylethyl]-1,3-benzoxazole-2-carboxamide
英文别名
——
N-[(1R)-1-phenylethyl]-1,3-benzoxazole-2-carboxamide化学式
CAS
——
化学式
C16H14N2O2
mdl
——
分子量
266.29
InChiKey
KHOVAHLIRHWUCN-LLVKDONJSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.3
  • 重原子数:
    20
  • 可旋转键数:
    3
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.12
  • 拓扑面积:
    55.1
  • 氢给体数:
    1
  • 氢受体数:
    3

文献信息

  • [EN] INDOLE DERIVATIVES FOR USE IN MEDICINE<br/>[FR] DÉRIVÉS INDOLÉS DESTINÉS À ÊTRE UTILISÉS DANS LE DOMAINE DE LA MÉDECINE
    申请人:IOMET PHARMA LTD
    公开号:WO2015150097A1
    公开(公告)日:2015-10-08
    Provided is a tryptophan-2,3-dioxygenase (TDO) and/or indoleamine-2,3-dioxygenase (IDO) inhibitor compound for use in medicine, which compound comprises the following formula: wherein X1, X2, X3, X4, and X5 may be the same or different and each is independently selected from C, N and O; each atom having a dotted line may independently have a double bond or a single bond, provided that valencies at each atom are maintained; each R1, R2, R3, R4, R5, and R7 may be present or absent and may be the same or different and is selected from H and a substituted or unsubstituted organic group, provided that the number of such R groups present is such that the valencies of X1, X2, X3, X4, and X5 are maintained; one or two R6 groups may be present and are selected from H and a substituted or unsubstituted organic group, provided that the number of R6 groups present is such that the valency of the carbon atom to which they are attached is maintained, and provided that at least one R6 is an organic group comprising an atom double-bonded to an oxygen atom (preferably a carbonyl group or a sulphonyl group) at an α-, β-, or γ-position to the carbon atom to which the R6 is attached and in which the atom double-bonded to an oxygen atom is also bonded to a hetero-atom.
    提供了一种色氨酸2,3-双加氧酶(TDO)和/或吲哚酮-2,3-双加氧酶(IDO)抑制剂化合物,用于医学,该化合物包括以下结构式:其中X1、X2、X3、X4和X5可以相同或不同,并且每个独立地选择自C、N和O;每个有点线的原子可以独立地具有双键或单键,前提是保持每个原子的价;每个R1、R2、R3、R4、R5和R7可以存在或不存在,并且可以相同或不同,并且选择自H和取代或未取代的有机基团,前提是存在这样的R基团的数量使得X1、X2、X3、X4和X5的价被保持;可以存在一个或两个R6基团,并且选择自H和取代或未取代的有机基团,前提是存在这样的R6基团的数量使得它们附着的碳原子的价被保持,并且前提是至少有一个R6是包含一个与氧原子双键的原子的有机基团(优选为一个羰基基团或一个磺酰基基团),在其中与氧原子双键的原子也与一个杂原子键合。
  • INDOLE DERIVATIVES FOR USE IN MEDICINE
    申请人:IOMet Pharma Ltd.
    公开号:US20190084933A1
    公开(公告)日:2019-03-21
    Provided is a tryptophan-2,3-dioxygenase (TDO) and/or indoleamine-2,3-dioxygenase (IDO) inhibitor compound for use in medicine, which compound comprises the following formula: wherein X 1 , X 2 , X 3 , X 4 , and X 5 may be the same or different and each is independently selected from C, N and O; each atom having a dotted line may independently have a double bond or a single bond, provided that valencies at each atom arc maintained; each R 1 , R 2 , R 3 , R 4 , and R 7 may be present or absent and may be the same or different and is selected from H and a substituted or unsubstituted organic group, provided that the number of such R groups present is such that the valencies of X 1 , X 2 , X 3 , X 4 , and X 5 are maintained; one or two R 6 groups may be present and are selected from H and a substituted or unsubstituted organic group, provided that the number of R 6 groups present is such that the valency of the carbon atom to which they are attached is maintained, and provided that at least one R 6 is an organic group comprising an atom double-bonded to an oxygen atom (preferably a carbonyl group or a sulphonyl group) at an α-, β-, or γ-position to the carbon atom to which the R 6 is attached and in which the atom double-bonded to an oxygen atom is also bonded to a hetero-atom.
    提供一种色氨酸-2,3-双加氧酶(TDO)和/或吲哚胺-2,3-双加氧酶(IDO)抑制剂化合物,用于医学,该化合物包括以下式子:其中X1、X2、X3、X4和X5可以相同或不同,并且每个独立地选择自C、N和O;每个有点线的原子可以独立地具有双键或单键,前提是每个原子的价被保持;每个R1、R2、R3、R4和R7可以存在或不存在,可以相同或不同,并且选择自H和取代或未取代的有机基团,前提是存在的这些R基团的数量使得X1、X2、X3、X4和X5的价被保持;可以存在一或两个R6基团,选择自H和取代或未取代的有机基团,前提是存在的这些R6基团的数量使得它们附着的碳原子的价被保持,并且至少有一个R6是包含一个双键连接到α-、β-或γ-位置的氧原子(优选为羰基基团或磺酰基团)的有机基团,并且其中双键连接到氧原子的原子也与杂原子相结合。
  • Indole derivatives for use in medicine
    申请人:IOmet Pharma Ltd.
    公开号:US10167257B2
    公开(公告)日:2019-01-01
    Provided is a tryptophan-2,3-dioxygenase (TDO) and/or indoleamine-2,3-dioxygenase (IDO) inhibitor compound for use in medicine, which compound comprises the following formula: wherein X1, X2, X3, X4, and X5 may be the same or different and each is independently selected from C, N and O; each atom having a dotted line may independently have a double bond or a single bond, provided that valencies at each atom are maintained; each R1, R2, R3, R4, R5, and R7 may be present or absent and may be the same or different and is selected from H and a substituted or unsubstituted organic group, provided that the number of such R groups present is such that the valencies of X1, X2, X3, X4, and X5 are maintained; one or two R6 groups may be present and are selected from H and a substituted or unsubstituted organic group, provided that the number of R6 groups present is such that the valency of the carbon atom to which they are attached is maintained, and provided that at least one R6 is an organic group comprising an atom double-bonded to an oxygen atom (preferably a carbonyl group or a sulphonyl group) at an α-, β-, or γ-position to the carbon atom to which the R6 is attached and in which the atom double-bonded to an oxygen atom is also bonded to a hetero-atom.
    本发明提供了一种用于医药的色氨酸-2,3-二氧化酶(TDO)和/或吲哚胺-2,3-二氧化酶(IDO)抑制剂化合物,该化合物包括下式:其中 X1、X2、X3、X4 和 X5 可以相同或不同,且各自独立地选自 C、N 和 O;每个带有虚线的原子可以独立地具有双键或单键,前提是每个原子上的价保持不变;每个 R1、R2、R3、R4、R5 和 R7 可以存在或不存在,可以相同或不同,并且可以选自 H 和取代或未取代的有机基团,条件是存在的此类 R 基团的数目使得 X1、X2、X3、X4 和 X5 的化合价保持不变;可存在一个或两个 R6 基团,它们选自 H 和一个取代或未取代的有机基团,条件是所存在的 R6 基团的数目必须保证它们所连接的碳原子的价保持不变、且至少有一个 R6 是有机基团,该有机基团包含一个与氧原子(最好是羰基或磺酰基)在与 R6 所连接的碳原子的 α-、β- 或 γ- 位置上双键结合的原子,其中与氧原子双键结合的原子还与杂原子结合。
查看更多

同类化合物

(N-{4-[(6-溴-2-氧代-1,3-苯并恶唑-3(2H)-基)磺酰基]苯基}乙酰胺) 钙离子载体A23187半镁盐 荧光增白剂EBF 苯并恶唑胺 苯并恶唑的取代物 苯并恶唑甲磺酰氯 苯并恶唑基-2-甲酰基-S-乙基-异缩氨基硫脲 苯并恶唑-2-羧酸酰肼 苯并恶唑-2-磺酸 苯并恶唑-2-甲酸 苯并恶唑-2-甲磺酸钠 苯并恶唑-2-乙酸 苯并恶唑 苯并噁唑-5-甲酸 苯并噁唑-2-羧酸乙酯 苯并噁唑-2-甲醛 苯并噁唑,4,7-二氯-2-(氯甲基)- 苯并噁唑,2-叠氮- 苯并噁唑,2-(氯甲基)-4,7-二氟- 苯并[d]恶唑-7-甲酸甲酯 苯并[d]恶唑-5-硼酸频哪醇酯 苯并[d]噁唑-6-甲醛 苯并[d]噁唑-2-羧酸甲酯 苯并[d]噁唑-2-甲醇 苯并[D]恶唑-7-胺 苯并[D]噁唑-4-基氨基甲酸叔丁酯 苯并[D]噁唑-2-羧酸钾 苯并-13C6-噁唑 离子载体 碘化二氢2-[3-(5,6-二氯-1,3-二乙基-1,3--2H-苯并咪唑-2-亚基)丙-1-烯基]-3-乙基-5-苯基苯并噁唑正离子 硫代偏糖醛 甲酰胺,N-乙基-N-[6-[(3-甲酰基苯氧基)甲基]-2-苯并噁唑基]- 甲酰胺,N-[6-(溴甲基)-2-苯并噁唑基]-N-乙基- 甲基硫酸1-甲基-8-[(甲基氨基甲酰)氧代]喹啉正离子 甲基6-氨基-1,3-苯并恶唑-2-羧酸酯 甲基2-氨基-1,3-苯并恶唑-5-羧酸酯 甲基1,3-苯并恶唑-2-基乙酸酯 甲基-2-乙基-1,3-苯并唑-5-羧酸乙酯 甲基-1,3-苯并唑-5-羧酸乙酯 环戊二烯并[e][1,3]恶嗪-5,6-二胺 环戊二烯并[d][1,3]恶嗪-6,7-二胺 溴氯唑酮 溴化二氢2-[3-[1-[4-[(乙酰氨基)磺基基]丁基]-5,6-二氯-3-乙基-1,3--2H-苯并咪唑-2-亚基]丙-1-烯基]-3-乙基-5-苯基苯并噁唑正离子 氰基二硫代亚氨酸(6-氯-2-氧代-3(2H)-苯并恶唑基)甲基甲基酯 氰基-二硫代亚氨酸甲基(2-氧代-3(2H)-苯并恶唑基)甲基酯 氯唑沙宗-2-13C-3-15N-羟基-18O 氯唑沙宗 氯化3-乙基-2-[2-(1-乙基-2,5-二甲基-1H-吡咯-3-基)乙烯基]苯并恶唑翁盐 昂唑司特 拂来星-d2